In one paragraphReview in Metabolites, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Julia R ZickusDepartment of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.ORCID 0000-0002-3134-0310 José S EnriquezDepartment of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.ORCID 0000-0002-9119-8176 Paytience SmithDepartment of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Bill T SunDepartment of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Muxin WangDepartment of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Aldo MoralesDepartment of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Pratip K BhattacharyaDepartment of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.ORCID 0000-0002-0625-252X Shivanand PudakalakattiDepartment of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.ORCID 0000-0002-6210-2104 Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8MUNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCERP50CA083639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C · 1999 to 2015
$33.0MTexas Center for Cancer NanomedicineU54CA151668 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LIBUTTI, STEVEN K. · 2010 to 2014
$12.4MTargeted Hyperpolarized Molecular Beacons for Colorectal Cancer DetectionR21EB031217 · NIBIB · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BHATTACHARYA, PRATIP K. · 2021 to 2023
$648k(PQC5)Early Detection Pancreatic Cancer by Hyperpolarized Silicon NanoparticlesR21CA185536 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BHATTACHARYA, PRATIP K. · 2014 to 2015
$383kReal Time Metabolic Imaging to Interrogate Early Detection and Prevention of Pancreatic CancerF99CA284365 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ENRIQUEZ, JOSE S · 2023 to 2024
$74kCancer Prevention and Research Institute of Texas RP150701, RP220270, RP220313, RP250090Department of Defence PC131680, HT94252310664NCI NIH HHS CA016672NCI NIH HHS F99 CA284365NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA083639NCI NIH HHS R21 CA185536NCI NIH HHS U54 CA151668NCI NIH HHS U54 CA151668, P50 CA083639, R21 CA185536, F99 CA284365NIBIB NIH HHS R21 EB031217NIBIB NIH HHS R21EB031217
6 · The paper itselfAbstract
Nuclear magnetic resonance (NMR) spectroscopy is a routinely used analytical tool for studying chemical entities of varying molecular sizes, ranging from approximately 20 Da to ~45 kDa, and in some cases even larger. Over the past two decades, the use of NMR spectroscopy has significantly expanded to the study of metabolomics. In this medium-sized review, the application of NMR-based metabolomics in the diagnosis, therapeutic intervention, and guidance of therapy for various types of brain cancer is discussed.
Indexed as
brain cancerdiagnosismetabolomicsNMR spectroscopytherapeutic intervention
Identifiers
PMID41002991
PMCPMC12472021
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390